Node | MIE / KE / AO | # Shared AOPs | Betweenness Centrality | Edge Count | In degree | Out degree | In/Out Ratio |
---|---|---|---|---|---|---|---|
Increased, recruitment of pro-inflammatory cells | KE | 3 | 0.088235 | 9 | 5 | 4 | 1.25 |
Loss of alveolar membrane integrity | KE | 3 | 0.127451 | 8 | 4 | 4 | 1 |
Increased secretion, pro-inflammatory mediators | KE | 3 | 0.0918 | 8 | 4 | 4 | 1 |
Increased ROS synthesis | KE | 3 | 0.054367 | 7 | 3 | 4 | 0.75 |
Activation, T-helper type 2 cells | KE | 2 | 0.057041 | 5 | 2 | 3 | 0.666666667 |
Surfactant function inhibition | KE | 2 | 0.032531 | 5 | 3 | 2 | 1.5 |
ECM deposition | KE | 2 | 0.018717 | 5 | 3 | 2 | 1.5 |
Fibroblast / myofibroblast proliferation | KE | 2 | 0.016934 | 5 | 3 | 2 | 1.5 |
Increased, TFF2 release | KE | 1 | 0.005348 | 4 | 1 | 3 | 0.333333333 |
Cellular toxicity | KE | 1 | 0.027184 | 3 | 1 | 2 | 0.5 |
Activation, epithelial cells | KE | 1 | 0.016934 | 3 | 2 | 1 | 2 |
Destruction of ECM, proteinases and elastases | KE | 1 | 0.010695 | 3 | 2 | 1 | 2 |
Chronic inflammation | KE | 1 | 0.004902 | 3 | 1 | 2 | 0.5 |
Increased, serum amyloid A expression | KE | 1 | 0.032086 | 2 | 1 | 1 | 1 |
Formation, serum amyloid A-high density lipoprotein complex | KE | 1 | 0.026738 | 2 | 1 | 1 | 1 |
Reduced lung volume | KE | 1 | 0.026738 | 2 | 1 | 1 | 1 |
Increased, systemic cholesterol | KE | 1 | 0.019608 | 2 | 1 | 1 | 1 |
Increased, DNA damage and mutation | KE | 1 | 0.016043 | 2 | 1 | 1 | 1 |
Impaired oxygenation | KE | 1 | 0.01426 | 2 | 1 | 1 | 1 |
Foam cell formation | KE | 1 | 0.010695 | 2 | 1 | 1 | 1 |
Increased, cell proliferation | KE | 1 | 0.008913 | 2 | 1 | 1 | 1 |
Loss of proteinase / antiproteinase enzymatic balance | KE | 1 | 0.006684 | 2 | 1 | 1 | 1 |
Increased secretion, pro-inflammatory and pro-fibrotic mediators | KE | 1 | 0.006239 | 2 | 1 | 1 | 1 |
Blood components leak into the lungs | KE | 1 | 0.005348 | 2 | 1 | 1 | 1 |
Increased, IL-33 expression | KE | 1 | 0.001783 | 2 | 1 | 1 | 1 |
Lung fibrosis | AO | 2 | 0 | 2 | 2 | 0 | Undefined |
Interaction with the lung resident cell membrane components | MIE | 2 | 0 | 2 | 0 | 2 | 0 |
Lung cancer | AO | 1 | 0 | 1 | 1 | 0 | Undefined |
Plaque progression | AO | 1 | 0 | 1 | 1 | 0 | Undefined |
Acute inhalation toxicity | AO | 1 | 0 | 1 | 1 | 0 | Undefined |
Lung emphysema | AO | 1 | 0 | 1 | 1 | 0 | Undefined |
Frustrated phagocytosis | MIE | 1 | 0 | 1 | 0 | 1 | 0 |
Interaction with resident cell membrane components TLR2/4 binding | MIE | 1 | 0 | 1 | 0 | 1 | 0 |
Interaction with epithelial cell membrane | MIE | 1 | 0 | 1 | 0 | 1 | 0 |
Interaction with lung surfactant | MIE | 1 | 0 | 1 | 0 | 1 | 0 |